COGT Cogent Biosciences, Inc.
Cogent Biosciences, Inc. (COGT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $242.6M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Morris Arlene 2 fills | Director | Sell 10b5-1 | 45,510 | $37.12 | $1.7M | 3,161 −93.5% of holding | |
| Fairmount Funds Management LLC | Director | Sell | 7,000,000 | $34.66 | $242.6M | 5,503,418 −56% of holding | |
| Fairmount Funds Management LLC | Director | Sell | 3,500,000 | $36.40 | $127.4M | 5,503,418 −38.9% of holding | |
| Robinson John Edward | Chief Scientific Officer | Sell | 90,000 | $38.74 | $3.5M | 140,002 −39.1% of holding | |
| Sachs Jessica | Chief Medical Officer | Sell | 82,642 | $38.70 | $3.2M | 133,938 −38.2% of holding | |
| Green John L. | Chief Financial Officer | Sell | 77,000 | $38.68 | $3.0M | 131,834 −36.9% of holding | |
| Kearns Evan | Chief Legal Officer | Sell | 65,000 | $38.70 | $2.5M | 109,398 −37.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.